Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Fluticasone propionate/formoterol for COPD management: a randomized controlled trial.

Papi A, Dokic D, Tzimas W, Mészáros I, Olech-Cudzik A, Koroknai Z, McAulay K, Mersmann S, Dalvi PS, Overend T.

Int J Chron Obstruct Pulmon Dis. 2017 Jul 5;12:1961-1971. doi: 10.2147/COPD.S136527. eCollection 2017.

2.

Implementation of GOLD consensus report in real life: results from the Velletri-Lariano (VELA) cohort.

De Filippi G, Lallini M, De Riggi G, Marchetti G, Dimartino CM, Russetti AM, Ferrari E, Pistelli R, Magnoni MS, Riparbelli M, Rizzi A, Angeletti P.

Multidiscip Respir Med. 2017 Jul 17;12:18. doi: 10.1186/s40248-017-0095-2. eCollection 2017.

3.

Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids.

Sonnappa S, Martin R, Israel E, Postma D, van Aalderen W, Burden A, Usmani OS, Price DB; Respiratory Effectiveness Group, Small Airways Study Group.

PLoS One. 2017 Jun 15;12(6):e0178112. doi: 10.1371/journal.pone.0178112. eCollection 2017.

4.

Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.

Morjaria JB, Rigby A, Morice AH.

Lung. 2017 Jun;195(3):281-288. doi: 10.1007/s00408-017-9990-8. Epub 2017 Mar 3.

5.

Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study.

Price DB, Russell R, Mares R, Burden A, Skinner D, Mikkelsen H, Ding C, Brice R, Chavannes NH, Kocks JW, Stephens JW, Haughney J.

PLoS One. 2016 Sep 22;11(9):e0162903. doi: 10.1371/journal.pone.0162903. eCollection 2016.

6.

Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.

Miravitlles M, D'Urzo A, Singh D, Koblizek V.

Respir Res. 2016 Sep 10;17(1):112. doi: 10.1186/s12931-016-0425-5. Review.

7.

Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.

Singh D, Corradi M, Spinola M, Petruzzelli S, Papi A.

NPJ Prim Care Respir Med. 2016 Jun 16;26:16030. doi: 10.1038/npjpcrm.2016.30. Review.

8.

Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis.

Festic E, Bansal V, Gupta E, Scanlon PD.

COPD. 2016 Jun;13(3):312-26. doi: 10.3109/15412555.2015.1081162. Epub 2015 Dec 8.

9.

Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.

Scott DA, Woods B, Thompson JC, Clark JF, Hawkins N, Chambers M, Celli BR, Calverley P.

BMC Pulm Med. 2015 Nov 11;15:145. doi: 10.1186/s12890-015-0138-4.

10.

Inhaled Corticosteroids Increase the Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Cohort Study.

Lee MC, Lee CH, Chien SC, Chang JH, She HL, Wang JY, Yu MC.

Medicine (Baltimore). 2015 Oct;94(42):e1723. doi: 10.1097/MD.0000000000001723.

11.

A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease.

D'Urzo A, Donohue JF, Kardos P, Miravitlles M, Price D.

Expert Opin Pharmacother. 2015;16(12):1845-60. doi: 10.1517/14656566.2015.1067682. Review.

12.

The risk and outcomes of pneumonia in patients on inhaled corticosteroids.

Sibila O, Soto-Gomez N, Restrepo MI.

Pulm Pharmacol Ther. 2015 Jun;32:130-6. doi: 10.1016/j.pupt.2015.04.001. Epub 2015 May 5. Review.

13.

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD.

Gao J, Pleasants RA.

Int J Chron Obstruct Pulmon Dis. 2015 Apr 15;10:775-89. doi: 10.2147/COPD.S80656. eCollection 2015. Review.

14.

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.

Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.

Respir Res. 2015 Feb 15;16:25. doi: 10.1186/s12931-015-0184-8. Review.

15.

Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm.

Wilkie M, Finch S, Schembri S.

COPD. 2015;12(5):582-90. doi: 10.3109/15412555.2014.995288. Epub 2015 Mar 16. Review.

16.

Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?

Festic E, Scanlon PD.

Am J Respir Crit Care Med. 2015 Jan 15;191(2):141-8. doi: 10.1164/rccm.201409-1654PP. Review.

17.

Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Babu KS, Kastelik JA, Morjaria JB.

Br J Clin Pharmacol. 2014 Aug;78(2):282-300. doi: 10.1111/bcp.12334. Review.

18.

Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis.

Ni S, Fu Z, Zhao J, Liu H.

J Thorac Dis. 2014 Jul;6(7):971-8. doi: 10.3978/j.issn.2072-1439.2014.07.03.

19.

Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis.

Oba Y, Lone NA.

Int J Chron Obstruct Pulmon Dis. 2014 May 12;9:469-79. doi: 10.2147/COPD.S48492. eCollection 2014. Review.

20.

AIMAR survey on COPD phenotypes.

Magnoni MS, Rizzi A, Visconti A, Donner CF.

Multidiscip Respir Med. 2014 Mar 17;9(1):16. doi: 10.1186/2049-6958-9-16.

Supplemental Content

Support Center